XML 42 R19.htm IDEA: XBRL DOCUMENT
v3.25.4

Government Contributions | 12 Months Ended
--- | ---
Dec. 31, 2025
Payables and Accruals [Abstract] |
Government Contributions | Government Contributions In May of 2020, the Company received a funding commitment from the Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Response Fund (SRF), formerly Strategic Innovation Fund (SIF), for a total of CAD $175.6 million ($125.6 million), collectively “Government Contribution 1”, which is intended to support research and development efforts related to the discovery of antibodies to treat COVID-19, and to build technology and manufacturing infrastructure for antibody drugs against future pandemic threats. In May of 2023, the Company entered into multi-year contribution agreements with the Government of Canada and the Government of British Columbia for a total of CAD $300.0 million ($222.3 million), collectively “Government Contribution 2”. These investments are intended to build new capabilities in Canada to develop, manufacture, and deliver antibody medicines to patients through Phase 1 clinical trials and build expertise in translational science, technical operations, and clinical operations and research. Under these contribution agreements, the Company has agreed to certain financial and non-financial covenants and other obligations, including cross-default provisions associated with other Canadian funding, and restrictive covenants on dividend payments or other shareholder distributions that would prevent the Company from satisfying its obligations under the arrangement. The Company has granted notice and consent rights to the counterparties upon certain events related to a change in control (as defined in the agreements) of the Company. Other obligations in relation to Government Contribution 2 include the maintenance of certain gross capital expenditures in Canada, certain research and development expenditures in Canada, and the achievement of certain employment headcount requirements in Canada. Pursuant to the agreements, certain customary events of default, such as the Company’s breach of its covenants and obligations under the respective agreements, its insolvency, winding up or dissolution, and other similar events, may permit the Governments of Canada and British Columbia to declare an event of default under the respective agreements. Upon an event of default, subject to applicable cure, the Governments of Canada and British Columbia may exercise a number of remedies, including suspending or terminating funding under the respective agreements, demanding repayment of funding previously received and/or terminating the respective agreements. The government contributions and their associated conditional repayments are not secured by any of AbCellera’s assets or those of the projects. Government Contribution 1 From inception to December 31, 2025, the Company incurred CAD $175.6 million ($134.6 million) in expenditures, of which CAD $58.7 million ($46.1 million) relates to the maximum claim amount under phase 1 of the agreement. Such amounts are not repayable. The maximum claim amount under phase 2 of the funding commitment is CAD $116.9 million ($88.5 million) where repayment is conditional on achieving certain revenue thresholds during the seven years starting the year after the completion of the funded project. Repayment will be calculated as a percentage rate of the Company’s revenue, with payment made on an annual basis during the repayment period of fifteen years. The Company has made the full investment and has received the maximum available funding under the agreement as of December 31, 2025. Government Contribution 2 In May of 2023, the Government of Canada committed up to CAD $225.0 million ($166.7 million) of which CAD $56.2 million ($41.6 million) is non-repayable, CAD $78.8 million ($58.4 million) is repayable, and CAD $90.0 million ($66.7 million) is conditionally repayable. Both the repayable and conditionally repayable amounts are repayable starting in 2033. The repayable funding is payable over fifteen years and the conditionally repayable portion repaid based on a computed percentage rate of the Company’s revenue over a period of up to fifteen years, at a factor of up to 1.4 times the original conditionally repayable grant. The agreement will expire on the later of April 30, 2047, or the date of the last repayment, unless earlier terminated. For the years ended December 31, 2024 and December 31, 2025, the Company incurred expenditures of CAD $38.3 million ($27.8 million) and CAD$53.5 million ($38.6 million), respectively, in regards to the funding commitment. In May of 2023, the Government of British Columbia committed up to CAD $75.0 million ($55.6 million) which includes partial reimbursement of certain eligible expenditures up to CAD $37.5 million ($27.8 million) towards eligible infrastructure investments paid over five years; and a CAD $37.5 million ($27.8 million) conditional portion paid upon achievement of certain defined milestones, including upon the Company’s undertaking of certain clinical trial activities in British Columbia. Up to a maximum of CAD $64.0 million ($48.0 million) may become payable starting in 2032, over up to fifteen years, conditional to the Company achieving revenue exceeding a given threshold. The agreement will expire on the earlier of 2047, or the date of the last payment, unless earlier terminated, as prescribed in the agreement. For the years ended December 31, 2024 and December 31, 2025, the Company incurred expenditures of CAD $18.7 million ($13.8 million) and CAD $1.0 million ($0.7 million), respectively, in regards to the funding commitment. Impact to Consolidated Financial Statements At December 31, 2024 and 2025, the Company recognized the following on the consolidated balance sheets:
| December 31, 2024
|  |  | Deferred Government Contribution
| Accounts Receivable |  | Government Grant 1 |  |  |  | Total
|  | Non-repayable |  | Conditionally Repayable 2 |  | Repayable |  |
Government Contribution 1 (Canada) | $ | 12,262 |  |  | $ | 5,593 |  |  | $ | 80,114 |  |  | $ | — |  |  | $ | 85,707 |
Government Contribution 2 (Canada) | 17,016 |  |  | 7,098 |  |  | — |  |  | 36,978 |  |  | 44,076 |
Government Contribution 2 (British Columbia) | 21,413 |  |  | — |  |  | 26,781 |  |  | — |  |  | 26,781 |
Other Government Grants | — |  |  | 987 |  |  | — |  |  | — |  |  | 987 |
Total | $ | 50,691 |  |  | $ | 13,678 |  |  | $ | 106,895 |  |  | $ | 36,978 |  |  | $ | 157,551 |
Current | $ | 21,709 |  |  | $ | 4,125 |  |  | $ | 3,533 |  |  | $ | — |  |  | $ | 7,658 |
Long-term | $ | 28,982 |  |  | $ | 9,553 |  |  | $ | 103,362 |  |  | $ | 36,978 |  |  | $ | 149,893 |
1 Government Contributions are amortized into other income over the weighted average life of approximately 8 years. 2 No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable.
| December 31, 2025
|  |  | Deferred Government Contribution
| Accounts Receivable |  | Government Grant 1 |  |  |  | Total
|  | Non-repayable |  | Conditionally Repayable 2 |  | Repayable |  |
Government Contribution 1 (Canada) | $ | — |  |  | $ | 2,003 |  |  | $ | 78,032 |  |  | $ | — |  |  | $ | 80,035 |
Government Contribution 2 (Canada) | 15,343 |  |  | 10,701 |  |  | — |  |  | 66,499 |  |  | 77,200 |
Government Contribution 2 (British Columbia) | 18,249 |  |  | — |  |  | 25,215 |  |  | — |  |  | 25,215 |
Other Government Grants | — |  |  | 986 |  |  | — |  |  | — |  |  | 986 |
Total | $ | 33,592 |  |  | $ | 13,690 |  |  | $ | 103,247 |  |  | $ | 66,499 |  |  | $ | 183,436 |
Current | $ | 20,916 |  |  | $ | 2,652 |  |  | $ | 6,331 |  |  | $ | — |  |  | $ | 8,983 |
Long-term | $ | 12,676 |  |  | $ | 11,038 |  |  | $ | 96,916 |  |  | $ | 66,499 |  |  | $ | 174,453 |
1 Government Contributions are amortized into other income over the weighted average life of approximately 24 years. 2 No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable.

X
- Definition The entire disclosure for government assistance. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4 + Details
Name: | us-gaap_GovernmentAssistanceTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration